FORM 4

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *					2. Issuer Name and Ticker or Trading Symbol						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
ZASLOFF MICHAEL A					Amphastar Pharmaceuticals, Inc. [AMPH]							_X_ Director		109	6 Owner		
(Last)	(First)	(Mi	ddle)	3	B. Date	. Date of Earliest Transaction (MM/DD/YYYY)					Officer (giv	e title below	/)Oth	er (specify b	pelow)		
C/O AMPHASTAR PHARMACEUTICALS, INC., 11570					3/5/2024												
6TH STREET																	
	(Street)				4. If Amendment, Date Original Filed (MM/DD/YYYY)							6. Individual or Joint/Group Filing (Check Applicable Line)					
RANCHO CUCAMONGA, CA 91730 (City) (State) (Zip)				730							_X _ Form filed by One Reporting Person Form filed by More than One Reporting Person						
(0)	ity) (Sua	(E1 <u>1</u>		I - Non-D	erivat	ive Se	curities A	Acqu	iired, D	isposed	l of, or	Bene	eficially Owne	d			
1. Title of Security (Instr. 3)			?. Trans. Date			3. Trans. Code (Instr. 8)		4. Securities Acquired Disposed of (D) (Instr. 3, 4 and 5)			F	(Instr. 3 and 4) Form: Direct (D)		Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	V	Amoun		Price	:				4)	
Common Stock 3/5			3/5/2024			S		9,389	D	\$47.0626	6 (1)			24,437	D		
Common Stock				3/5/2024	024		s		3,111	D	\$47.526	6 (2)	2		21,326	D	
	Tab	le II - Der	ivative	Securition	es Ben	eficiall	ly Owne	d (e.g	g., puts	calls,	warran	ts, o	ptions, conver	tible secu	ırities)		
1. Title of Derivate Security (Instr. 3)	ccurity Conversion or Exercise Price of Derivative Security Security Date Execution Date, if any		on (Instr.	Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			ies a	6. Date Expiration Date Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Title Amount or Number of Shares		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

- (1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$46.435 to \$47.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
- (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$47.435 to \$47.68, inclusive.

Reporting Owners

Panarting Overar Nama / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
ZASLOFF MICHAEL A						
C/O AMPHASTAR PHARMACEUTICALS, INC.	X					
11570 6TH STREET	11					
RANCHO CUCAMONGA, CA 91730						

Signatures

/s/ Eva Wen, by power of attorney	3/6/2024			
** Signature of Penarting Person	Date			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.